Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: Topical and intravenous administration in a rat model of deep arterial injury

Journal of Vascular Surgery

Volumn 33, Issue 5, 2001, Pages 1072-1079

  Söderström, Torbjörn ^a   Hedner, Ulla ^b   Arnljots, Björn ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; FIBRINOLYTIC AGENT; HEPARIN; PHENYLALANYL PHENYLALANYL ARGINYL RECOMBINANT FVIIA; PHENYLALANYL-PHENYLALANYL-ARGINYL-RECOMBINANT FVIIA;

ANIMAL; ARTICLE; BLEEDING; BLOOD CLOTTING; CAROTID ARTERY; DRUG EFFECT; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; THROMBOSIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; BLOOD COAGULATION; BLOOD LOSS, SURGICAL; CAROTID ARTERIES; FACTOR VIIA; FIBRINOLYTIC AGENTS; HEMOSTASIS; HEPARIN; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

EID: 0035347163     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2001.112808     Document Type: Article

References (43)

1. Williams GM. Complications of vascular surgery. Surg Clin North Am 1993;73:323-5.
2. Bouquet J, Voltz C, Nace L, Fieve G, Larcan A. Complications de la chirurgie vasculaire. J Mal Vasc 1998;23:17-34.
3. Boston Dr., Malouf A, Barry WH. Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. Clin Cardiol 1996;19:536-42.
4. Oweida SW, Roubin GS, Smith RB III, Salam AA. Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. J Vasc Surg 1990;12:310-5.
5. Wheeldon N, Cumberland D. Pharmacologic prevention of acute ischemic complications of coronary angioplasty. Cathet Cardiovasc Diagn 1997;42:249-56.
6. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999;138(4 Pt 2):287-96.
7. The global use of strategies to open occluded coronary arteries (GUSTO) IIa investigators: randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.
8. Antman EM. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
9. Tomaru T, Nakamura F, Fujimori Y, Omata M, Kawai S, Okada R, et al. Local treatment with antithrombotic drugs can prevent thrombus formation: an angioscopic and angiographic study. J Am Coll Cardiol 1995;26:1325-32.
10. Nunes GL, Thomas CN, Hanson SR, Barry JJ, King SB III, Scott NA. Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel-coated balloon. Circulation 1995;92:1697-700.
11. Okada T, Bark DH, May berg MR. Local anticoagulation without systemic effect using a polymer heparin delivery system. Stroke 1988;19:1470-6.
12. Khouri RK, Koudsi B, Kaiding F, Ornberg RL, Wun TC. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg 1993;30:398-402; discussion 402-4.
13. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989;134:1087-97.
14. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989;86:2839-43.
15. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993;91:2253-9.
16. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-71.
17. Marmur JD, Thiruvikraman SV, Fyte BS, Guha A, Sharma SK, Ambrose JA, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-32.
18. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Otiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9.
19. Kirchhofer D, Nemerson Y. Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr Opin Biotechnol 1996;7:386-91.
20. Mann KG, van’t Veer C, Cawthern K, Butenas S. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis 1998;9 Suppl 1:S3-7.
21. Chen LB, Buchanan JM, Mitogenic activity of blood components, I: thrombin and prothrombin. Proc Natl Acad Sci USA 1975;72:131-5.
22. Graham DJ, Alexander JJ. The effects of thrombin on bovine aortic endothelial and smooth muscle cells. J Vasc Surg 1990;11:307-13.
23. McNamara CA, Sarembock IJ, Bachhuber BG, Stouffer GA, Ragosta M, Barry W, et al. Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin Thromb Hemost 1996;22:139-44.
24. Sorensen BB, Persson E, Freskgard PO, Kjalke M, Ezban M, Williams T, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor [published erratum appears in J Biol Chem 1997;272:16708]. J Biol Chem 1997;272:11863-8.
25. Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997;25:341-6.
26. Holst J, Kristensen AT, Kristensen HI, Ezban M, Hedner U. Local application of recombinant active-site inhibited human clotting factor Vila reduces thrombus weight and improves patency in a rabbit venous thrombosis model. Eur J Vasc Endovasc Surg 1998;15:515-20.
27. Golino P, Ragni M, Cirillo P, D’Andree D, Scognamiglio A, Ravera A, et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998;82:39-46.
28. Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995;74:464-72.
29. Harker LA, Hanson SR, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997;78:736-41.
30. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996;26 Suppl 1:76-82.
31. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-50.
32. Acland RD. Microsurgery practice manual. St Louis: CV Mosby; 1980, p. 58-9.
33. Thim L, Bioern S, Christensen M, Nicolaisen EM, Lund HT, Pedersen AH, et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988;27:7785-93.
34. Arnljots B, Wieslander J, Dougan P, Salemark L. Prevention of microvascular thrombosis with low dose tissue plasminogen activator. Plast Reconstr Surg 1992;90;281-8.
35. Arnljots B, Dougan P, Wieslander JB, Salemark L, Bergqvist D. Platelet accumulation and thrombus formation after microarterial injury: an experimental study in rabbits. Scand J Plast Reconstr Surg Hand Surg 1994;28:167-75.
36. Arnljots B, Dahlbäck B. Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits. J Clin Invest 1995;95:1987-93.
37. Arnljots B, Dahlbäck B. Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis. Arterioscler Thromb Vase Biol 1995;15:937-41.
38. Arnljots B, Bergqvist D. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: A specific thrombin inhibitor. Plast Reconstr Surg 1995;95:894-900.
39. Kristensen AT, Kristensen HI, Elm T, Arnljots B, Söderström T, Holst J, et al. FFR-rFVIIa effectively inhibits tissue factor activity in segments of human and rabbit arteries in an ex vivo assay. Blood 1998;92:10 Suppl 1:546a.
40. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997;96:646-52.
41. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus hirudin, a specific thrombin inhibitor. Circulation 1989;89:657-65.
42. Agnelli G, Renga C, Weitz JI, Nenci GG, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 1992;80:960-5.
43. Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade. Circulation 1999;99:1951-8.